Optiscan Imaging Limited announced submission of its FDA (United States Food and Drug Administration) Pre-Market Notification (510(k)) application for the InVivage® device intended for oral tissue imaging. InVivage® is a next generation, non-invasive, instantaneous form of oral imaging, targeting the severe health consequences of late-stage diagnosis of oral cancers and precancerous lesions. The technology platform enables real-time, non-destructive, 3D, in-vivo imaging at the sub-cellular level which aims to provide physicians, surgeons and pathologists with high resolution microscopic images intraoperatively that can be used to assist with diagnosis and treatment of various oral pathologies.